{"nctId":"NCT01603641","briefTitle":"BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity","startDateStruct":{"date":"2012-11-05","type":"ACTUAL"},"conditions":["Pediatrics","Muscle Spasticity","Cerebral Palsy"],"count":370,"armGroups":[{"label":"BOTOX®","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum Toxin Type A"]}],"interventions":[{"name":"Botulinum Toxin Type A","otherNames":["BOTOX®","OnabotulinumtoxinA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Minimum weight of 10 kilograms (kg)/22 pounds (lb)\n* Cerebral palsy with dynamic muscle contracture of the ankle\n\nExclusion Criteria:\n\n* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease\n* Uncontrolled epilepsy\n* Botulinum Toxin therapy of any serotype for any condition within the last 3 months\n* History of surgical intervention of the lower study leg within 1 year, or planned surgery of any limb during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)","description":"An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":367},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Pyrexia","Bronchitis"]}}}